Cargando…

Identification of potent compounds against SARs-CoV-2: An in-silico based drug searching against Mpro

The worldwide pandemic of coronavirus disease 2019 (COVID-19) along with the various newly discovered major SARS-CoV-2 variants, including B.1.1.7, B.1.351, and B.1.1.28, constitute the Variant of Concerns (VOC). It's difficult to keep these variants from spreading over the planet. As a result...

Descripción completa

Detalles Bibliográficos
Autores principales: Hassam, Muhammad, Bashir, Muhammad Arslan, Shafi, Sarah, Zahra, Noor-ul-Ain, Khan, Kanwal, Jalal, Khurshid, Siddiqui, Hina, Uddin, Reaz
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Ltd. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9635257/
https://www.ncbi.nlm.nih.gov/pubmed/36370580
http://dx.doi.org/10.1016/j.compbiomed.2022.106284
_version_ 1784824674618703872
author Hassam, Muhammad
Bashir, Muhammad Arslan
Shafi, Sarah
Zahra, Noor-ul-Ain
Khan, Kanwal
Jalal, Khurshid
Siddiqui, Hina
Uddin, Reaz
author_facet Hassam, Muhammad
Bashir, Muhammad Arslan
Shafi, Sarah
Zahra, Noor-ul-Ain
Khan, Kanwal
Jalal, Khurshid
Siddiqui, Hina
Uddin, Reaz
author_sort Hassam, Muhammad
collection PubMed
description The worldwide pandemic of coronavirus disease 2019 (COVID-19) along with the various newly discovered major SARS-CoV-2 variants, including B.1.1.7, B.1.351, and B.1.1.28, constitute the Variant of Concerns (VOC). It's difficult to keep these variants from spreading over the planet. As a result of these VOCs, the fifth wave has already begun in several countries. The rapid spread of VOCs is posing a serious threat to human civilization. There is currently no specific medicine available for the treatment of COVID-19. Here, we present the findings of methods that used a combination of structure-assisted drug design, virtual screening, and high-throughput screening to swiftly generate lead compounds against Mpro protein of SARs-CoV-2. Therapeutics, in addition to vaccinations, are an essential element of the healthcare response to COVID-19's persistent threat. In the current study, we designed the efficient compounds that may combat all emerging variants of SARs-CoV-2 by targeting the common Mpro protein. The present study was aimed to discover new compounds that may be proposed as new therapeutic agents to treat COVID-19 infection without any adverse effects. For this purpose, a computational-based virtual screening of 352 in-house synthesized compounds library was performed through molecular docking and Molecular Dynamics (MD) simulation approach. As a result, four novel potent compounds were successfully shortlisted by implementing certain pharmacological, physiological, and ADMET criteria i.e., compounds 3, 4, 21, and 22. Furthermore, MD simulations were performed to evaluate the stability and dynamic behavior of these compounds with Mpro complex for about 30 ns. Eventually, compound 22 was found to be highly potent against Mpro protein and was further evaluated by applying 100 ns simulations. Our findings showed that these shortlisted compounds may have potency to treat the COVID-19 infection for which further experimental validation is proposed as part of a follow-up investigation.
format Online
Article
Text
id pubmed-9635257
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Elsevier Ltd.
record_format MEDLINE/PubMed
spelling pubmed-96352572022-11-04 Identification of potent compounds against SARs-CoV-2: An in-silico based drug searching against Mpro Hassam, Muhammad Bashir, Muhammad Arslan Shafi, Sarah Zahra, Noor-ul-Ain Khan, Kanwal Jalal, Khurshid Siddiqui, Hina Uddin, Reaz Comput Biol Med Article The worldwide pandemic of coronavirus disease 2019 (COVID-19) along with the various newly discovered major SARS-CoV-2 variants, including B.1.1.7, B.1.351, and B.1.1.28, constitute the Variant of Concerns (VOC). It's difficult to keep these variants from spreading over the planet. As a result of these VOCs, the fifth wave has already begun in several countries. The rapid spread of VOCs is posing a serious threat to human civilization. There is currently no specific medicine available for the treatment of COVID-19. Here, we present the findings of methods that used a combination of structure-assisted drug design, virtual screening, and high-throughput screening to swiftly generate lead compounds against Mpro protein of SARs-CoV-2. Therapeutics, in addition to vaccinations, are an essential element of the healthcare response to COVID-19's persistent threat. In the current study, we designed the efficient compounds that may combat all emerging variants of SARs-CoV-2 by targeting the common Mpro protein. The present study was aimed to discover new compounds that may be proposed as new therapeutic agents to treat COVID-19 infection without any adverse effects. For this purpose, a computational-based virtual screening of 352 in-house synthesized compounds library was performed through molecular docking and Molecular Dynamics (MD) simulation approach. As a result, four novel potent compounds were successfully shortlisted by implementing certain pharmacological, physiological, and ADMET criteria i.e., compounds 3, 4, 21, and 22. Furthermore, MD simulations were performed to evaluate the stability and dynamic behavior of these compounds with Mpro complex for about 30 ns. Eventually, compound 22 was found to be highly potent against Mpro protein and was further evaluated by applying 100 ns simulations. Our findings showed that these shortlisted compounds may have potency to treat the COVID-19 infection for which further experimental validation is proposed as part of a follow-up investigation. Elsevier Ltd. 2022-12 2022-11-04 /pmc/articles/PMC9635257/ /pubmed/36370580 http://dx.doi.org/10.1016/j.compbiomed.2022.106284 Text en © 2022 Elsevier Ltd. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Article
Hassam, Muhammad
Bashir, Muhammad Arslan
Shafi, Sarah
Zahra, Noor-ul-Ain
Khan, Kanwal
Jalal, Khurshid
Siddiqui, Hina
Uddin, Reaz
Identification of potent compounds against SARs-CoV-2: An in-silico based drug searching against Mpro
title Identification of potent compounds against SARs-CoV-2: An in-silico based drug searching against Mpro
title_full Identification of potent compounds against SARs-CoV-2: An in-silico based drug searching against Mpro
title_fullStr Identification of potent compounds against SARs-CoV-2: An in-silico based drug searching against Mpro
title_full_unstemmed Identification of potent compounds against SARs-CoV-2: An in-silico based drug searching against Mpro
title_short Identification of potent compounds against SARs-CoV-2: An in-silico based drug searching against Mpro
title_sort identification of potent compounds against sars-cov-2: an in-silico based drug searching against mpro
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9635257/
https://www.ncbi.nlm.nih.gov/pubmed/36370580
http://dx.doi.org/10.1016/j.compbiomed.2022.106284
work_keys_str_mv AT hassammuhammad identificationofpotentcompoundsagainstsarscov2aninsilicobaseddrugsearchingagainstmpro
AT bashirmuhammadarslan identificationofpotentcompoundsagainstsarscov2aninsilicobaseddrugsearchingagainstmpro
AT shafisarah identificationofpotentcompoundsagainstsarscov2aninsilicobaseddrugsearchingagainstmpro
AT zahranoorulain identificationofpotentcompoundsagainstsarscov2aninsilicobaseddrugsearchingagainstmpro
AT khankanwal identificationofpotentcompoundsagainstsarscov2aninsilicobaseddrugsearchingagainstmpro
AT jalalkhurshid identificationofpotentcompoundsagainstsarscov2aninsilicobaseddrugsearchingagainstmpro
AT siddiquihina identificationofpotentcompoundsagainstsarscov2aninsilicobaseddrugsearchingagainstmpro
AT uddinreaz identificationofpotentcompoundsagainstsarscov2aninsilicobaseddrugsearchingagainstmpro